Could an antihypertensive halt new-onset T1DM progression?
Off-label use of oral verapamil could be an option for some patients without contraindications, researchers say
The blood pressure-lowering drug verapamil may delay the progression of type 1 diabetes, lower insulin requirements and reduce pro-inflammatory cytokines for at least two years, a small yet promising study shows.
Given the lack of oral therapeutics available for type 1 diabetes (T1DM), researchers say the antihypertensive could potentially reduce patients’ reliance on exogenous insulin.
“Off-label use of once-daily, oral, slow-release verapamil provides an additional approach that can be considered at a one-by
